|
|
 |
|
|
| Digoxin Ph Eur, BP, USP |
|
 |
|
| Digoxin is a purified cardiac glycoside extracted from the foxglove plant. Its corresponding aglycone is digoxigenin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. |
|
|
CAS number
|
20830-75-5
|
|
Molecular Formula
|
C41H64O14
|
|
Molecular Weight
|
780.938
|
|
Quality Standards
|
Ph Eur, BP, USP
|
|
Material Safety Data Sheet
|
Available on request
|
|
Availability
|
For your requirements of evaluation, Pilots and Commercial procurement
|
|
Packing
|
As per buyers requirement
|
|
Product Reference
|
MA-ZB-133-D
|
|
|
|
|
|
|
|
|
|
 |
NOTE: 
- Manus Aktteva, India is successfully representing suppliers, manufacturers from INDIA, suppliers, manufacturers from CHINA, and fulfilling the requirements of buyers from EUROPE, USA, South America, Japan, Korea, Taiwan, Australia, & middle-east.
Keywords: New Molecules, patents, R&D, cas, cas number, product, supplier, suppliers, vendor, vendors, price, prices, api, apis, active pharmaceutical ingredient, ingredients, importer, exporter, distributor, import, export, sale, producer, manufacturer, synthesizer, synthesis, gmp, cgmp, fda, dmf, cgmp, cos, inventory, stock, prompt shipment, compounding, compound, research, development, patent, r and d, pharma
- Please note that products falling in to controlled substance category shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
Product enquiries may please be sent to info@manusaktteva.in, udeetjbanker@gmail.com, jdbanker@gmail.com
PATENTS:
- => Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
=> Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
|
|
|
|
|